Comparing the Efficacy of Fosnetupitant, an NK<sub>1</sub> Receptor Antagonist in CDDP-Based Regimens, with That of Fosaprepitant and Aprepitant: A Retrospective Observational Study-Reference-Cited by-同舟云学术

Comparing the Efficacy of Fosnetupitant, an NK<sub>1</sub> Receptor Antagonist in CDDP-Based Regimens, with That of Fosaprepitant and Aprepitant: A Retrospective Observational Study

Published:2024-03-25 Issue:3 Volume:47 Page:692-697
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biological & Pharmaceutical Bulletin

Author:

Inano Hiroshi¹,Morimoto Yoshihito²,Kitagawa Kanata¹,Shibuya Akito¹,Nakagomi Kozue¹,Ota Tomohiro¹,Anzo Yuri¹,Miyauchi Rika²,Shono Aiko³,Watanabe Kazuhiro²,Otori Katsuya¹⁴

Affiliation:

1. Department of Pharmacy, Kitasato University Hospital

2. Education and Research Center for Clinical Pharmacy, Showa Pharmaceutical University

3. Laboratory of Social Pharmacy and Regulatory Science, Showa Pharmaceutical University

4. Laboratory of Pharmacy Practice and Science I, Research and Education Center for Clinical Pharmacy, School of Pharmacy, Kitasato University

Publisher

Pharmaceutical Society of Japan

Link

https://www.jstage.jst.go.jp/article/bpb/47/3/47_b23-00819/_pdf

Reference26 articles.

1. 1) Morrow GR, Hickok JT, Burish TG, Rosenthal SN. Frequency and clinical implications of delayed nausea and delayed emesis. Am. J. Clin. Oncol., 19, 199–203 (1996).

2. 2) Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J. Effect of postchemotherapy nausea and vomiting on health-related quality of life. Support. Care Cancer, 5, 307–313 (1997).

3. 3) Schwartzberg LS, Modiano MR, Rapoport BL, Chasen MR, Gridelli C, Urban L, Poma A, Arora S, Navari RM, Schnadig ID. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol., 16, 1071–1078 (2015).

4. 4) Ithimakin S, Theeratrakul P, Laocharoenkiat A, Nimmannit A, Akewanlop C, Soparattanapaisarn N, Techawattanawanna S, Korphaisarn K, Danchaivijitr P. Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy. Support. Care Cancer, 28, 5335–5342 (2020).

5. 5) Aogi K, Takeuchi H, Saeki T, et al. Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: update summary of the 2015 Japan Society of Clinical Oncology clinical practice guidelines for antiemesis. Int. J. Clin. Oncol., 26, 1–17 (2021).